These findings reveal that whole-brain FC meaningfully predicts tau PET in preclinical Alzheimer’s disease, particularly in regions affected in advanced disease, and are relevant across the Alzheimer’s disease clinical spectrum in individuals with elevated tau PET burden. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.